Skip to main content
    E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.47
    +0.29 (+2.59%)

    Market Cap: $335.52M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    +21.59%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.46
    Range$-0.66 - $-0.26
    4 analysts
    Revenue Consensus
    $14M
    Range$11M - $16M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.48 - $-0.33
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.36-11.0%
    60d ago$-0.36-11.0%
    30d ago$-0.36-11.0%
    7d ago$-0.36-11.0%
    Current$-0.41
    Revenue Consensus
    $16M
    Range$14M - $18M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.46---
    Jun 26
    Reported Aug 10
    		$-0.67$-0.37-81.08%Miss+21.2%
    Mar 26
    Reported May 11
    		$-0.45$-0.57+21.05%Beat+57.5%
    Dec 25
    Reported Feb 9
    		$-0.42N/A+52.27%Beat+60.0%
    Sep 25
    Reported Nov 17
    		$-0.87$-1.01+13.86%Beat+36.0%
    Jun 25
    Reported Aug 11
    		$-0.85$-0.88+3.41%Beat+20.6%
    Mar 25
    Reported May 12
    		$-1.06$-1.14+7.02%Beat+27.9%
    Dec 24
    Reported Feb 10
    		$-1.05$-1.35+22.22%Beat+33.5%
    Sep 24
    Reported Nov 25
    		$-1.36$-0.92-47.83%Miss-2.3%
    Jun 24
    Reported Aug 5
    		$-1.07$-1.41+24.11%Beat+42.5%
    Mar 24
    Reported May 6
    		$-1.47$-1.40-5.00%Miss+17.9%
    Dec 23
    Reported Feb 7
    		$-1.58$-1.23-28.46%Miss-13.7%
    Sep 23
    Reported Nov 20
    		$-1.33$-2.21+39.82%Beat-4.7%
    Jun 23
    Reported Aug 7
    		$-1.86$-2.19+15.07%Beat-21.6%
    Mar 23
    Reported May 8
    		$-1.79$-1.93+7.25%Beat-9.8%
    Dec 22
    Reported Feb 7
    		$-1.39$-1.60+13.13%Beat+6.1%
    Sep 22
    Reported Nov 21
    		$-1.27$-1.35+5.93%Beat-4.1%
    Jun 22
    Reported Aug 8
    		$-1.53$-1.39-10.07%Miss-28.6%
    Mar 22
    Reported May 9
    		$-1.63$-1.41-15.60%Miss-49.5%
    Dec 21
    Reported Feb 8
    		$-1.48$-1.11-33.33%Miss-261.0%
    Sep 21
    Reported Nov 22
    		$-1.22$-1.19-2.52%Miss+16.4%
    Jun 21
    Reported Aug 5
    		$-1.19$-1.29+7.75%Beat-67.6%
    Mar 21
    Reported May 6
    		$-1.09$-0.97-12.37%Miss-263.3%
    Dec 20
    Reported Feb 8
    		$-0.41$-0.77+46.75%Beat-163.1%
    Sep 20
    Reported Nov 23
    		$-1.46$-0.97-50.52%Miss-431.8%
    Jun 20
    Reported Aug 4
    		$-0.71$-0.96+26.04%Beat-315.2%
    Mar 20
    Reported May 6
    		$-0.30N/A+58.33%Beat-250.0%
    Dec 19
    Reported Feb 6
    		$0.65$0.60+8.33%Beat-48.0%
    Sep 19
    Reported Nov 21
    		$0.44$0.56-21.43%Miss-66.2%
    Jun 19
    Reported Aug 6
    		$0.33$0.17+94.12%Beat-66.0%
    Mar 19
    Reported May 7
    		$0.20$-0.05+500.00%Beat-67.2%
    Dec 18
    Reported Feb 6
    		$1.25$1.29-3.10%Miss+212.5%
    Sep 18
    Reported Nov 26
    		$1.30$1.19+9.24%Beat-30.1%
    Jun 18
    Reported Aug 7
    		$0.97$0.90+7.78%Beat+320.5%
    Mar 18
    Reported May 8
    		$0.61$0.25+144.00%Beat+317.9%
    Dec 17
    Reported Feb 7
    		$0.40$0.27+48.15%Beat+253.8%
    Sep 17
    Reported Nov 20
    		$1.86$2.13-12.68%Miss-
    Jun 17
    Reported Aug 7
    		$-0.44$-0.48+8.33%Beat-
    Mar 17
    Reported May 8
    		$-0.28$-0.38+26.32%Beat-
    Dec 16
    Reported Feb 8
    		$-0.26$-0.18-44.44%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.76EV/EBITDAN/A
    Price/FCF-9.03xFCF Yield-11.07%
    Profitability
    Profit Margin-96.90%Operating Margin-120.00%
    ROE-70.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-4.54x
    Current Ratio3.76xQuick Ratio3.76x
    Trading Statistics
    Beta0.96Avg Volume273.31K
    52-Week High$17.1552-Week Low$10.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.12
    SMA 20$12.25
    SMA 50$12.95
    SMA 200$13.33
    EMA 10$11.96
    EMA 20$12.26
    EMA 50$12.71
    EMA 200$12.67

    MACD

    Line: -0.35Signal: -0.26Hist: -0.10

    ADX

    ADX: 20.3+DI: 15.6-DI: 28.8

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down96.0
    PSAR$13.14

    Bollinger Bands

    Upper Band$13.26
    Lower Band$11.24
    %B Position1651%(Upper)
    Band Width0.11

    RSI (14-Day)

    Neutral
    39.2

    Momentum Oscillators

    Stoch %K7.3
    Stoch %D17.4
    Williams %R-85.9
    ROC (10d)-10.7%
    Momentum-1.37
    CCI (20d)-146.7
    MFI (14d)49.6

    Volatility Measures

    ATR (14d)$0.59(5.2%)
    StdDev (20d)0.51
    Hist Vol49.7%(High)

    Volume Flow

    VWAP$11.47
    OBV19.5M
    AD Line13.4M
    CMF (20d)-0.031

    Volume Metrics

    Avg Vol (20d)273.4K
    Vol Ratio0.7x
    VWMA (20d)$12.38

    Pivot Points

    R3$11.87
    R2$11.72
    R1$11.45
    Pivot Point$11.30
    S1$11.03
    S2$10.88
    S3$10.61

    Advanced Oscillators

    TSI-15.67
    Ultimate Osc44.4
    KST-66.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$14.36M$17.16M$18.61M$15.13M$18.31M$14.93M$16.96M$14.61M$17.97M$17.05M$18.00M$18.93M
    Cost of Revenue$0$0$0$1.28M$0$0$0$479,000$0$0$0$669,000
    Gross Profit$14.36M$17.16M$18.61M$15.13M$18.31M$14.93M$16.96M$14.61M$17.97M$17.05M$18.00M$18.93M
    Operating Expenses$31.59M$29.01M$29.87M$33.51M$37.21M$39.45M$40.50M$44.46M$42.16M$49.82M$52.89M$49.96M
    R&D$22.13M$19.44M$20.86M$23.81M$27.21M$28.07M$27.66M$30.78M$28.74M$35.59M$36.37M$36.17M
    SG&A$9.47M$9.57M$9.01M$9.70M$10.00M$11.39M$12.85M$13.68M$13.41M$14.23M$16.52M$13.79M
    Operating Income$-17,236,000$-11,852,000$-11,253,000$-18,386,000$-18,893,000$-24,527,000$-23,543,000$-29,854,000$-24,185,000$-32,766,000$-34,886,000$-31,030,000
    Interest Income$1.90M$2.08M$2.42M$2.07M$2.29M$2.29M$2.80M$3.18M$3.49M$3.81M$4.30M$4.66M
    Interest Expense$4.13M$3.32M$3.08M$2.39M$1.62M$1.71M$1.96M$2.58M$2.35M$2.56M$3.44M$3.15M
    Income Before Tax$-19,465,000$-13,084,000$-11,914,000$-18,668,000$-18,226,000$-23,949,000$-22,706,000$-29,186,000$-23,053,000$-31,520,000$-34,029,000$-29,517,000
    Income Tax Expense$36,000$7,000$24,000$32,000$29,000$-1,305,000$-416,000$-363,000$-395,000$-363,000$-622,000$-1,410,000
    Net Income$-19,501,000$-13,091,000$-11,938,000$-18,700,000$-18,255,000$-22,644,000$-22,290,000$-28,823,000$-22,658,000$-31,157,000$-33,407,000$-28,107,000
    EBITDA$-16,043,000$-10,341,000$-10,003,000$-14,997,000$-17,670,000$-22,508,000$-22,022,000$-30,577,000$-23,826,000$-32,120,000$-22,022,000$-30,425,000
    EBIT$-17,236,000$-11,852,000$-11,253,000$-16,281,000$-18,893,000$-24,527,000$-23,543,000$-29,854,000$-24,185,000$-32,766,000$-23,543,000$-31,030,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENTA

    News

    Wall Street Zen cuts Enanta Pharmaceuticals stock to Sell. Consensus target is USD 19.00.

    Wall Street Zen has downgraded Enanta Pharmaceuticals (ENTA) stock from Hold to Sell, maintaining a consensus target of USD 19.00. The company reported a fiscal third-quarter revenue of USD 14.36 million and a net loss...

    ad-hoc-news.de•10/15/26•Bearish

    Wall Street Zen cuts Enanta Pharmaceuticals stock to Sell. Consensus target is USD 19.00.

    Wall Street Zen has downgraded Enanta Pharmaceuticals (ENTA) from Hold to Sell, although the consensus target price remains at USD 19.00. This comes after Enanta reported a fiscal third-quarter revenue of USD 14.36...

    ad-hoc-news.de•10/15/26•Bearish

    Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

    Enanta Pharmaceuticals (NASDAQ:ENTA) announced it will present data for its investigational respiratory syncytial virus (RSV) treatment, zelicapavir...

    BioSpace•10/13/26•Somewhat-Bullish

    Wall Street Zen upgrades Enanta Pharmaceuticals stock to Hold

    Wall Street Zen has upgraded Enanta Pharmaceuticals (ENTA) stock from Sell to Hold after the company posted an adjusted loss of USD 0.67 per share and revenue of USD 14.36 million in its fiscal third quarter...

    AD HOC NEWS•10/8/26•Neutral

    Enanta Pharmaceuticals stock fell 2.78 percent on October 5

    Enanta Pharmaceuticals stock dropped by 2.78% on October 5, trading at USD 12.60. This decline follows the company's weak fiscal third-quarter results, which showed revenue of USD 14.36 million...

    AD HOC NEWS•10/5/26•Somewhat-Bearish

    ENTA Valuation and Fair Value

    P/E
    -4.8x
    Forward P/E
    44.0x
    P/FCF
    -9.0x
    PEG
    0.0x
    P/B
    3.3x
    See GNG's fair value

    ENTA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -120.0%
    Net margin
    -96.9%
    ROE
    -70.1%
    FCF margin
    -56.6%
    FCF yield
    -11.1%

    ENTA Competitors

    CompanyTicker
    Semler Scientific IncSMLR
    Arcturus Therapeutics Holdings IncARCT
    Orchestra BioMed Holdings Inc.OBIO
    Sanara Medtech IncSMTI
    Opus Genetics, Inc.IRD
    Canopy Growth CorpCGC
    Embecta CorpEMBC
    Indaptus Therapeutics IncINDP

    Sector: Healthcare

    ENTA Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ENTA Bull Case vs Bear Case

    Bull case

    • ENTA beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of ENTA's analyst ratings are Buy or Strong Buy.

    Bear case

    • ENTA has a -96.9% net profit margin.
    • ENTA's quarterly revenue changed -21.6% year over year.

    ENTA Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    -1.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.46

    Frequently Asked Questions About ENTA

    Does ENTA pay dividends?

    Enanta Pharmaceuticals Inc (ENTA) does not currently pay a regular dividend.

    What is ENTA's market cap?

    Enanta Pharmaceuticals Inc (ENTA) has a market capitalization of $335.52M with a current stock price of $11.47.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In